dc.creator | Oikonomou O., Sarrou S., Papagiannitsis C.C., Georgiadou S., Mantzarlis K., Zakynthinos E., Dalekos G.N., Petinaki E. | en |
dc.date.accessioned | 2023-01-31T09:41:02Z | |
dc.date.available | 2023-01-31T09:41:02Z | |
dc.date.issued | 2015 | |
dc.identifier | 10.1186/s12879-015-1297-x | |
dc.identifier.issn | 14712334 | |
dc.identifier.uri | http://hdl.handle.net/11615/77378 | |
dc.description.abstract | Background: Colistin-resistant/carbapenem-resistant Acinetobacter baumannii is a significant challenge for antibiotic treatment and infection control policies. Since 2012, in Central Greece an increase of colistin/pan- resistant A. baumannii has occurred, indicating the need for further analysis. Methods: A total of 86 colistin-resistant/carbapenem-resistant out of 1228 A. baumannii clinical isolates, consecutively collected between 2012 and 2014 in a tertiary Greek hospital of Central Greece, as well as one environmental isolate from surveillance cultures were studied. Molecular typing and mechanisms of resistance to colistin and to carbapenems were assessed, whereas, epidemiological and clinical data of the patients were reviewed. Results: During the study period, the rate of colistin resistance gradually increased and reached 21.1 % in 2014. All colistin-resistant/carbapenem-resistant A. baumannii belonged to 3LST ST101 clone that corresponds to the international clonal lineage II. Carbapenem resistance was associated with the presence of bla oxa-23-like, while resistance to colistin probably correlated with G54E and R109H amino acid substitutions in PmrA and PmrC, respectively. Conclusions: Epidemiological data of the patients indicated that the first detection of colistin-resistant/carbapenem-resistant ST101 clone in the University Hospital of Larissa (UHL) was associated with a patient who previously had received colistin, while, the movement of the infected patients into the hospital probably resulted to its spread. © 2015 Oikonomou et al. | en |
dc.language.iso | en | en |
dc.source | BMC Infectious Diseases | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84952871316&doi=10.1186%2fs12879-015-1297-x&partnerID=40&md5=6ffd22b55567167a79d9efe90d715bfd | |
dc.subject | aminoglycoside antibiotic agent | en |
dc.subject | bacterial protein | en |
dc.subject | carbapenem | en |
dc.subject | colistin | en |
dc.subject | daptomycin | en |
dc.subject | fosfomycin | en |
dc.subject | protein PmrA | en |
dc.subject | protein PmrC | en |
dc.subject | quinoline derived antiinfective agent | en |
dc.subject | tigecycline | en |
dc.subject | unclassified drug | en |
dc.subject | antiinfective agent | en |
dc.subject | carbapenem derivative | en |
dc.subject | colistin | en |
dc.subject | Acinetobacter baumannii | en |
dc.subject | Acinetobacter infection | en |
dc.subject | aged | en |
dc.subject | amino acid substitution | en |
dc.subject | antibiotic resistance | en |
dc.subject | antibiotic sensitivity | en |
dc.subject | Article | en |
dc.subject | bacterial gene | en |
dc.subject | bacterial strain | en |
dc.subject | bacterium identification | en |
dc.subject | bacterium isolate | en |
dc.subject | blood culture | en |
dc.subject | bloodstream infection | en |
dc.subject | brain ventriculitis | en |
dc.subject | chronic kidney failure | en |
dc.subject | chronic liver disease | en |
dc.subject | chronic lung disease | en |
dc.subject | comorbidity | en |
dc.subject | controlled study | en |
dc.subject | diabetes mellitus | en |
dc.subject | disease surveillance | en |
dc.subject | DNA extraction | en |
dc.subject | epidemic | en |
dc.subject | female | en |
dc.subject | fever | en |
dc.subject | gene mutation | en |
dc.subject | Greece | en |
dc.subject | heart disease | en |
dc.subject | human | en |
dc.subject | IpxA gene | en |
dc.subject | IpxD gene | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | minimum inhibitory concentration | en |
dc.subject | molecular typing | en |
dc.subject | neurologic disease | en |
dc.subject | pmrCAB gene | en |
dc.subject | pneumonia | en |
dc.subject | polymerase chain reaction | en |
dc.subject | prevalence | en |
dc.subject | pyelonephritis | en |
dc.subject | ventilator associated pneumonia | en |
dc.subject | Acinetobacter baumannii | en |
dc.subject | Acinetobacter Infections | en |
dc.subject | drug effects | en |
dc.subject | hospital | en |
dc.subject | isolation and purification | en |
dc.subject | microbial sensitivity test | en |
dc.subject | microbiology | en |
dc.subject | middle aged | en |
dc.subject | multidrug resistance | en |
dc.subject | pulsed field gel electrophoresis | en |
dc.subject | Acinetobacter baumannii | en |
dc.subject | Acinetobacter Infections | en |
dc.subject | Aged | en |
dc.subject | Anti-Bacterial Agents | en |
dc.subject | Carbapenems | en |
dc.subject | Colistin | en |
dc.subject | Drug Resistance, Multiple, Bacterial | en |
dc.subject | Electrophoresis, Gel, Pulsed-Field | en |
dc.subject | Female | en |
dc.subject | Greece | en |
dc.subject | Hospitals | en |
dc.subject | Humans | en |
dc.subject | Male | en |
dc.subject | Microbial Sensitivity Tests | en |
dc.subject | Middle Aged | en |
dc.subject | Molecular Typing | en |
dc.subject | BioMed Central Ltd. | en |
dc.title | Rapid dissemination of colistin and carbapenem resistant Acinetobacter baumannii in Central Greece: Mechanisms of resistance, molecular identification and epidemiological data | en |
dc.type | journalArticle | en |